Developing new products for real-time intraoperative image-guided surgeries including cancer imaging agent LS301-IT (Leading Preclinical & Nonclinical Development; Design of NCT05900986 Clinical Study Objectives & Endpoints; Commercial Indications). Designing & developing augmented reality (AR), mixed reality (MR), and extended reality (XR) devices to visualize novel fluorescence tumor-targeting agents during surgery for complete removal of tumors. Exploring opportunities to incorporate… Show more Developing new products for real-time intraoperative image-guided surgeries including cancer imaging agent LS301-IT (Leading Preclinical & Nonclinical Development; Design of NCT05900986 Clinical Study Objectives & Endpoints; Commercial Indications). Designing & developing augmented reality (AR), mixed reality (MR), and extended reality (XR) devices to visualize novel fluorescence tumor-targeting agents during surgery for complete removal of tumors. Exploring opportunities to incorporate predictive analytics and artificial intelligence (e.g., machine learning, deep learning) into the operating room to improve patient treatment and care. Check us out: https://integrotheranostics.com/ Show less

Applying industry experience to de-risk and develop novel medical devices, technologies, and therapeutics in the university for transfer to industry partners and translation to clinics, hospitals, and homes. Current products include: 1) Molecular imaging system including cancer viewing goggles (augmented/mixed reality) and tumor-specific contrast agent to aid in surgical removal of tumors, and 2) Unique medical device coatings that minimize tissue damage, blunt inflammation, reduce pain, and… Show more Applying industry experience to de-risk and develop novel medical devices, technologies, and therapeutics in the university for transfer to industry partners and translation to clinics, hospitals, and homes. Current products include: 1) Molecular imaging system including cancer viewing goggles (augmented/mixed reality) and tumor-specific contrast agent to aid in surgical removal of tumors, and 2) Unique medical device coatings that minimize tissue damage, blunt inflammation, reduce pain, and minimize infections. Additional early-stage development projects include novel drug combinations for new therapeutic uses in immuno-oncology, infectious diseases, autoimmune diseases, and wound care. Also, development of Regulatory strategy for Software as a Medical Device (SaMD) for artificial intelligence (machine & deep learning) and for wearables & smartphones (Apps). Show less

Responsible for development and implementation of Kypha's patented rapid diagnostic tests in a dozen clinical settings across the USA including clinics, ICUs, and reference testing labs. Also responsible for the portfolio of point-of-care Comp ACT Assays which are being developed for diagnosing and monitoring of acute infections, trauma, and auto-immune diseases. Applying FDA Regulatory requirements including Quality Management System and Design Controls while developing novel, rapid… Show more Responsible for development and implementation of Kypha's patented rapid diagnostic tests in a dozen clinical settings across the USA including clinics, ICUs, and reference testing labs. Also responsible for the portfolio of point-of-care Comp ACT Assays which are being developed for diagnosing and monitoring of acute infections, trauma, and auto-immune diseases. Applying FDA Regulatory requirements including Quality Management System and Design Controls while developing novel, rapid single-plex and multiplex diagnostic products for use in point-of-care IVDs, for analytical/process development, and for research purposes only. Products serve the medical, companion animal, and agriculture industries as well as the Dept. of Defense. Expertise with lateral flow, gravity flow, vacuum flow, and microfluidic/lab-on-a-chip platforms for detection of proteins and nucleic acids. Show less